**Core Concept**
Statins are a class of lipid-lowering medications that inhibit the enzyme responsible for the rate-limiting step in cholesterol biosynthesis, a crucial process in the production of cholesterol in the liver. This enzyme is a key target for statins, which aim to reduce the liver's ability to synthesize cholesterol.

**Why the Correct Answer is Right**
Statins specifically inhibit HMG-CoA reductase, an enzyme that catalyzes the reduction of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) to mevalonate, a crucial intermediate in the cholesterol biosynthesis pathway. By inhibiting this enzyme, statins effectively reduce the liver's ability to produce cholesterol, leading to decreased circulating cholesterol levels. This mechanism is central to the therapeutic action of statins in managing hypercholesterolemia.

**Why Each Wrong Option is Incorrect**
**Option A:** Acyl CoA synthetase is not the target enzyme for statins. This enzyme is involved in the activation of fatty acids, but it is not directly involved in cholesterol biosynthesis.

**Option B:** Acyl CoA reductase is not a recognized enzyme in the cholesterol biosynthesis pathway. While it may be involved in other metabolic processes, it is not a target for statins.

**Option C:** HMG-CoA synthetase is an enzyme involved in the cholesterol biosynthesis pathway, but it is not the primary target for statins. This enzyme catalyzes the condensation of acetyl-CoA and acetoacetyl-CoA to form HMG-CoA, but it is not the rate-limiting step in the pathway.

**Clinical Pearl / High-Yield Fact**
Statins are a first-line treatment for hypercholesterolemia due to their efficacy in reducing LDL cholesterol levels and their relatively favorable safety profile. They are also used in combination with other lipid-lowering therapies, such as ezetimibe, to further reduce cholesterol levels.

**✓ Correct Answer: D. HMG CoA reductase**